- Home
- WEA vs CDXS Comparison
WEA vs CDXS Comparison
Compare WEA & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | CDXS |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 141.8M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | WEA | CDXS |
|---|---|---|
| Price | $10.98 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 20.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $10.16 | $1.05 |
| 52 Week High | $11.44 | $4.30 |
Technical Indicators
Market Signals| Indicator | WEA | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 33.75 |
| Support Level | $10.86 | N/A |
| Resistance Level | $11.04 | $2.56 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 12.77 | 16.18 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.